ELV — Elevance Health, Inc.

Is ELV overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Healthcare Plans

Oversold As of October 3, 2026

Elevance Health, Inc. (ELV) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Healthcare Plans) last closed at $386.43. The rating moved from Neutral to Oversold on October 1, 2026.

See all oversold Healthcare stocks →

AI analysis

Elevance Health, Inc. (ELV) benefits from a leading franchise in Medicare Advantage and a diversified revenue base that produces steady cash flows and strong negotiating leverage. Ongoing enrollment growth and defensive investor positioning support near‑term stability, while margin outcomes will hinge on managing rising pharmacy costs (notably GLP‑1s), competition on MA benefits, and regulatory developments around drug pricing. Operational discipline, utilization management, and successful network/provider strategies are the primary levers for upside; conversely, aggressive benefit competition or faster-than-expected pharmacy cost inflation would pressure earnings.

Key factors

  • Scale and market position across Medicare Advantage, Medicaid and commercial lines provide diversified, predictable revenue and strong negotiating leverage with providers and PBMs
  • Favorable demographic tailwinds (aging population) support continued MA enrollment growth and long-term revenue visibility
  • Defensive cash flows and low cyclicality relative to broader market, attracting flows in risk-off environments
  • Strong capital generation enables share repurchases and dividend support, bolstering per-share metrics
  • Operational initiatives and cost management can offset some medical cost pressure and benefit expansion
  • Exposure to pharmacy spend (GLP-1s and specialty drugs) creates both cost volatility and opportunities for care-management savings
  • Competitive dynamics in MA (aggressive $0-premium and benefit expansion by peers) represent both enrollment upside and margin tradeoffs

Risks

  • Intensifying Medicare Advantage competition (wider $0‑premium/benefit offerings) could compress margins and force higher benefit spend to retain/share members
  • Medicare drug-price negotiation and broader pricing/payer pressures (IRA-related) may alter medical cost and reimbursement dynamics, especially for high-cost therapies
  • Rapid growth in GLP-1/amylin therapies could materially increase pharmacy spend absent effective utilization management and formulary controls
  • Regulatory and political risk (rate setting, benefit mandates, oversight of MA plans) with uncertain implementation timing
  • Provider negotiation risk and potential network cost inflation if provider leverage increases
  • Macroeconomic or market liquidity shocks that reduce non‑premium investment income or pressure capital markets and M&A activity

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ELV — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.